2. Search Result
Search Result
Results for "

EET

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

9

Natural
Products

6

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-130494
    (±)11(12)-EET

    11,12-EET

    		 NOD-like Receptor (NLR) Cardiovascular Disease Inflammation/Immunology
    (±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective .
    (±)11(12)-EET
  • HY-130494S
    (±)11(12)-EET-d11

    (±)11,12-EET-d11

    		 NOD-like Receptor (NLR) Cardiovascular Disease Inflammation/Immunology
    (±)11(12)-EET-d11 is the deuterium labeled (±)11(12)-EET. (±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective .
    (±)11(12)-EET-d11
  • HY-139961S
    (±)14(15)-EET-d11

    		Isotope-Labeled Compounds Others
    (±)14(15)-EET-d11 is the deuterium labeled (±)14(15)-EET .
    (±)14(15)-EET-d11
  • HY-N12962A
    11R(12S)-EET

    		Others Others
    11R(12S)-EET is a cis-epoxytrienoic acid (EETs) derivative that is metabolized by cytoplasmic cyclooxygenases. Studies have shown that 14(R), 15(S)-, 11(S),12(R)-, and 8(S),9(R)-EETs are metabolized at significantly higher rates than their enantiomers. Enzyme-catalyzed hydration revealed that water addition was non-regioselective for the 11,12-EET enantiomers, whereas water addition occurred primarily at the C9 position for both enantiomers of 8,9-EET. These results suggest that the metabolic properties of 11R(12S)-EET and other EET enantiomers in enzyme-catalyzed processes are significantly affected by their stereostructures .
    11R(12S)-EET
  • HY-139937S
    (±)14(15)-EET-d11 methyl ester

    		Isotope-Labeled Compounds Others
    (±)14(15)-EET-d11 methyl ester is the deuterium labeled (±)14(15)-EET methyl ester .
    (±)14(15)-EET-d11 methyl ester
  • HY-N12962
    11S(12R)-EET

    		Others Others
    11S(12R)-EET is a dominant enantiomer of epoxytrienoic acid (EET) that is metabolized at a higher rate in rat organs. It shows enantiomeric-dependent reaction selectivity in hydration, especially in the case of 11,12-EET, where water addition is non-regioselective, while in 8,9-EET, water addition occurs mainly at the C9 position. In addition, 11S(12R)-EET generates diol products with specific stereochemistry through enzymatic hydration reactions, which are affected by the selective recognition of epoxidases, reaction conversion rates, and substrate binding parameters .
    11S(12R)-EET
  • HY-131721
    14,15-EET-SI

    		Drug Derivative Mitosis Others
    14,15-EET-SI is a sulfonimide (SI) analog metabolized from 14,15-EET, which is also an effective mitogen. 14,15-EET-SI can stimulate the incorporation of [3H] thymidine, activate pp60c-src and initiate the tyrosine kinase cascade, mediating their mitotic effects. Additionally, 14,15-EET-SI can increase cell proliferation as well as the expression of c-fos and egr-1 mRNA .
    14,15-EET-SI
  • HY-N12970
    14S(15R)-EET

    		Others Others
    14S(15R)-EET is an endogenous epoxytrienoic acid derivative that mainly exists in rat organs. By studying its metabolic process, it was found that its stereoselective hydration and formation of chiral diols were significantly affected by epoxidase. Different 14,15-EET enantiomers showed different regions and stereochemistry of hydration reactions, among which 14(R),15(S)-EET showed specific hydration for C15. These findings reveal the important role of epoxidase in the metabolism of endogenous EETs, and the differences in enzyme affinity and reaction rate for individual EET enantiomers may lead to their stereoselective metabolism .
    14S(15R)-EET
  • HY-168382A
    5S(6R)-EET

    		Prostaglandin Receptor Endogenous Metabolite Others
    5S(6R)-EET is the metabolite of Arachidonic acid (HY-109590). 5S(6R)-EET activates the synthesis of endogenous prostaglandin (PGE2), which inhibits the Na + absorption, increases the intracellular Ca 2+, and promotes the depolarization of transmembrane voltage. 5S(6R)-EET is more active than 5R(6S)-EET (HY-168382) .
    5S(6R)-EET
  • HY-168382
    5R(6S)-EET

    		Prostaglandin Receptor Endogenous Metabolite Others
    5R(6S)-EET is the metabolite of Arachidonic acid (HY-109590). 5R(6S)-EET activates the synthesis of endogenous prostaglandin (PGE2), which inhibits the Na + absorption, increases the intracellular Ca 2+, and promotes the depolarization of transmembrane voltage. 5R(6S)-EET exhibits stereoselectivity with less effectness than 5S(6R)-EET (HY-168382A) .
    5R(6S)-EET
  • HY-139938S
    (±)11(12)-EET methyl ester-d11

    11,12-EET methyl ester-d11; (±)11,12-EpETrE methyl ester-d11

    		 Isotope-Labeled Compounds Others
    (±)11(12)-EET-d11 methyl ester is the deuterium labeled (±)11(12)-EET methyl ester .
    (±)11(12)-EET methyl ester-d11
  • HY-120954
    14,15-EE-5(Z)-E

    		Endogenous Metabolite Cardiovascular Disease
    14,15-EE-5(Z)-E is a structural analogue of 14, 15-epoxide dicartrienoic acid (14,15-EET). 14,15-EE-5(Z)-E antagonizes the relaxation of vascular smooth muscle induced by EET .
    14,15-EE-5(Z)-E
  • HY-N12955
    8(R),9(S)-EET

    		Endogenous Metabolite Others
    8(R),9(S)-EET is an isomer of Epoxyeicosatrienoic acid (HY-113489). 8(R),9(S)-EET processes its metabolism with cytosolic epoxide hydrolase (cEH), with a binding affinity of Km of 41 μM .
    8(R),9(S)-EET
  • HY-150092S
    (2S,3R)-8(9)-EET-d11

    		Isotope-Labeled Compounds Drug Metabolite Others
    (2S,3R)-8(9)-EET-d11 is deuterium-labeled (2S,3R)-8(9)-EET (HY-150092) .
    (2S,3R)-8(9)-EET-d11
  • HY-150092
    8(S),9(R)-EET

    		Drug Metabolite Cardiovascular Disease
    8(S),9(R)-EET is an eicosanoid product of Arachidonic acid (AA; HY-109590) by cytochromes P450. 8(S),9(R)-EET dilates canine epicardial arterioles in a concentration-dependent manner with an EC50 value of 121 nM .
    8(S),9(R)-EET
  • HY-113489
    14,15-Epoxyeicosatrienoic acid

    14,15-EET

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease
    14,15-Epoxyeicosatrienoic acid (14,15-EET) is a metabolite of Arachidonic acid (HY-109590). 14,15-Epoxyeicosatrienoic acid is a potent inhibitor of in vivo platelet aggregation. 14,15-Epoxyeicosatrienoic acid facilitates astrocytic Aβ clearance. 14,15-Epoxyeicosatrienoic acid can be used for Alzheimer's Disease research .
    14,15-Epoxyeicosatrienoic acid
  • HY-165005
    14S(15R)-EET methyl ester

    		Drug Metabolite Metabolic Disease
    14S(15R)-EET methyl ester is an oxylipin and a cytochrome P450 metabolite of Arachidonic acid (HY-109590).
    14S(15R)-EET methyl ester
  • HY-150084
    (±)14,15-Epoxyeicosatrienoic acid

    (±)14(15)-EET

    		 Cytochrome P450 Mitosis Cancer
    (±)14,15-Epoxyeicosatrienoic acid ((±)14(15)-EET) is the Cytochrome P450 metabolite of arachidonic acid. While CYP3A4 may be involved in breast cancer cell growth, (±)14,15-Epoxyeicosatrienoic acid may promote mitosis and anchorage-dependent cloning through STAT3 affected by CYP3A4. (±)14,15-Epoxyeicosatrienoic acid exhibits STAT3-dependent cell growth promotion and may also participate in the autocrine/paracrine pathway that drives cell growth .
    (±)14,15-Epoxyeicosatrienoic acid
  • HY-113519
    14R(15S)-EET

    14R(15S)-EpETrE; 14R(15S)-Epoxyeicosatrienoic acid

    		 Drug Metabolite Metabolic Disease
    14R(15S)-EET (14R(15S)-EpETrE) is an oxylipin and a metabolite of Arachidonic acid (HY-109590) .
    14R(15S)-EET
  • HY-CE00578
    11,12-EET-CoA

    11,12-Epoxy-(5Z,8Z,14Z)-eicosatrienoyl-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    11,12-EET-CoA (11,12-Epoxy-(5Z,8Z,14Z)-eicosatrienoyl-coenzyme A) is a coenzyme A derivative.
    11,12-EET-CoA
  • HY-CE00870
    14,15-EET-CoA

    14,15-Epoxy-(5Z,8Z,11Z)-eicosatrienoyl-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    14,15-EET-CoA (14,15-Epoxy-(5Z,8Z,11Z)-eicosatrienoyl-coenzyme A) is an unsaturated fatty acyl-CoA.
    14,15-EET-CoA
  • HY-132184
    5,6-Epoxyeicosatrienoic acid

    5,6-EET; (±)5,6-EpETrE

    		 Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-135795
    1-Cyclohexyl-3-dodecyl urea

    CDU; N-Cyclohexyl-N-dodecyl urea; NCND

    		 Epoxide Hydrolase Cardiovascular Disease Metabolic Disease
    1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) is a highly selective soluble epoxide hydrolase (sEH) inhibitor. 1-Cyclohexyl-3-dodecyl urea (CDU; N-Cyclohexyl-N-dodecyl urea; NCND) increases epoxyeicosatrienoic acids (EETs) levels and lowers blood pressure in angiotensin II (Ang II) hypertension .
    1-Cyclohexyl-3-dodecyl urea
  • HY-143294
    sEH inhibitor-2

    		Epoxide Hydrolase Cardiovascular Disease
    sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection .
    sEH inhibitor-2
  • HY-132184S
    5,6-Epoxyeicosatrienoic acid-d11

    5,6-EET-d11; (±)5,6-EpETrE-d11

    		 Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .
    5,6-Epoxyeicosatrienoic acid-d11
  • HY-151616
    sEH inhibitor-10

    		Epoxide Hydrolase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases .
    sEH inhibitor-10
  • HY-165067
    14,15-EE-8(Z)-E

    14,15-Epoxyeicosa-8(Z)-enoic acid

    		 Drug Derivative Cardiovascular Disease
    14,15-EE-8(Z)-E (14,15-Epoxyeicosa-8(Z)-enoic acid) has potent vasodilator agonist activity in bovine coronary arteries. 14,15-EE-8(Z)-E is a 14,15-EET (HY-113489) analog. EETs represent important mediators of coronary vascular tone .
    14,15-EE-8(Z)-E
  • HY-130229
    (±)5,6-DHET lactone

    (±)5,6-DiHETrE lactone

    		 Drug Derivative Cardiovascular Disease
    5,6-DiHET lactone ((±)5,6-DiHETrE lactone) is a lactonized form of 5,6-EET and 5,6-DiHET. In solution, 5(6)-EET degrades into 5(6)-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS.1 5,6-DiHET potently induces vasodilation of isolated canine coronary arterioles, with 41 and 100% inhibition occurring at 0.01 and 100 pM, respectively. It also induces vasodilation in isolated human microvessels and increases intracellular calcium levels in a dose-dependent manner, an effect that can be blocked by the nitric oxide scavenger L-NAME.
    (±)5,6-DHET lactone
  • HY-139002
    CYP4Z1-IN-2

    		Cytochrome P450 Cancer
    CYP4Z1-IN-2 (compound 7) is a reversible inhibitor of CYP4Z1 (Ki=2.2 μM), which inhibits the production of 14,15-EET in breast cancer cells. CYP4Z1-IN-2 inhibits the CYP4Z1-mediated Luc-BE O-debenzylation reaction with an IC50 of 5.9 μM .
    CYP4Z1-IN-2
  • HY-N0515
    Ophiopogonin D

    		PPAR NF-κB Calcium Channel Cardiovascular Disease Inflammation/Immunology
    Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca 2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .
    Ophiopogonin D
  • HY-N0515R
    Ophiopogonin D (Standard)

    		PPAR NF-κB Calcium Channel Cardiovascular Disease Inflammation/Immunology
    Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .
    Ophiopogonin D (Standard)
  • HY-113038AR
    α-Hydroxyglutaric acid (disodium) (Standard)

    		Histone Demethylase Endogenous Metabolite Cancer
    Ophiopogonin D (Standard) is the analytical standard of Ophiopogonin D. This product is intended for research and analytical applications. Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .
    α-Hydroxyglutaric acid (disodium) (Standard)
  • HY-114759
    MS-PPOH

    		Cytochrome P450 Neurological Disease Metabolic Disease Cancer
    MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC50s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MS-PPOH
  • HY-121642
    SL-017

    		Others Others
    SL-017 is a novel photoacoustic sensitizer and a derivative of photofrin B. It can be taken up by cells to the maximum extent within 30 minutes and is mainly localized in mitochondria. After being activated by visible light or ultrasound, SL-017 can significantly increase the production of reactive oxygen species (ROS). Low concentrations of SL-017 can rapidly cause the loss of mitochondrial membrane potential. SL-017 can also cause mitochondrial fragmentation, a process that occurs after the loss of membrane potential. Epoxyeicosatrienoic acids (EETs) can alleviate the loss of mitochondrial membrane potential caused by SL-017, but the antioxidant ascorbic acid has no such effect. These characteristics indicate that SL-017 mainly targets mitochondria and exerts its cytotoxic effect by triggering the collapse of mitochondrial membrane potential, generating ROS, and causing mitochondrial fragmentation. As a novel photoacoustic sensitizer, SL-017 has potential application value in photodynamic therapy and sonodynamic therapy.
    SL-017

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: